HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 386 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,844,456 | +3.6% | 126,818 | -2.2% | 0.00% | – |
| Q2 2023 | $4,676,684 | -90.4% | 129,656 | -89.8% | 0.00% | -100.0% |
| Q1 2023 | $48,748,832 | -10.5% | 1,276,482 | +33.4% | 0.00% | -60.0% |
| Q4 2022 | $54,465,761 | +37.5% | 957,219 | -4.4% | 0.01% | +25.0% |
| Q3 2022 | $39,604,000 | -16.4% | 1,001,614 | -6.9% | 0.00% | -20.0% |
| Q2 2022 | $47,359,000 | +31.8% | 1,076,346 | +19.4% | 0.01% | +66.7% |
| Q1 2022 | $35,936,000 | +30.8% | 901,103 | +31.9% | 0.00% | +50.0% |
| Q4 2021 | $27,464,000 | -26.3% | 683,039 | -25.4% | 0.00% | -33.3% |
| Q3 2021 | $37,263,000 | -54.6% | 916,004 | -49.3% | 0.00% | -50.0% |
| Q2 2021 | $82,035,000 | +8.8% | 1,806,523 | -0.1% | 0.01% | 0.0% |
| Q1 2021 | $75,390,000 | +9.3% | 1,808,366 | +12.0% | 0.01% | 0.0% |
| Q4 2020 | $68,975,000 | +207.0% | 1,614,975 | +88.9% | 0.01% | +200.0% |
| Q3 2020 | $22,471,000 | +181.0% | 855,081 | +186.6% | 0.00% | +100.0% |
| Q2 2020 | $7,998,000 | -77.3% | 298,326 | -84.8% | 0.00% | -80.0% |
| Q1 2020 | $35,250,000 | -15.2% | 1,959,426 | -16.4% | 0.01% | 0.0% |
| Q4 2019 | $41,570,000 | +4.6% | 2,344,593 | -8.5% | 0.01% | 0.0% |
| Q3 2019 | $39,728,000 | -15.6% | 2,561,426 | -6.5% | 0.01% | 0.0% |
| Q2 2019 | $47,047,000 | +8.8% | 2,738,487 | +2.0% | 0.01% | 0.0% |
| Q1 2019 | $43,238,000 | +15.5% | 2,685,575 | +5.0% | 0.01% | 0.0% |
| Q4 2018 | $37,427,000 | -13.5% | 2,558,196 | +7.4% | 0.01% | 0.0% |
| Q3 2018 | $43,268,000 | +3.7% | 2,381,296 | -3.7% | 0.01% | 0.0% |
| Q2 2018 | $41,723,000 | -13.9% | 2,473,181 | 0.0% | 0.01% | -16.7% |
| Q1 2018 | $48,450,000 | -26.4% | 2,473,181 | -23.9% | 0.01% | -25.0% |
| Q4 2017 | $65,861,000 | -23.7% | 3,250,781 | -34.6% | 0.01% | -20.0% |
| Q3 2017 | $86,304,000 | +22.5% | 4,968,581 | -9.6% | 0.01% | +11.1% |
| Q2 2017 | $70,424,000 | -10.9% | 5,493,281 | -9.9% | 0.01% | -10.0% |
| Q1 2017 | $79,014,000 | +18.2% | 6,096,781 | -9.9% | 0.01% | +11.1% |
| Q4 2016 | $66,852,000 | -29.1% | 6,766,382 | -13.3% | 0.01% | -30.8% |
| Q3 2016 | $94,302,000 | +63.3% | 7,806,475 | +16.7% | 0.01% | +62.5% |
| Q2 2016 | $57,745,000 | +2.6% | 6,691,247 | +12.5% | 0.01% | 0.0% |
| Q1 2016 | $56,306,000 | -48.6% | 5,945,680 | -5.9% | 0.01% | -46.7% |
| Q4 2015 | $109,541,000 | +65.1% | 6,320,880 | +28.0% | 0.02% | +66.7% |
| Q3 2015 | $66,334,000 | -32.0% | 4,939,208 | +14.4% | 0.01% | -25.0% |
| Q2 2015 | $97,505,000 | +88.2% | 4,318,194 | +19.0% | 0.01% | +71.4% |
| Q1 2015 | $51,798,000 | +61.6% | 3,627,337 | +9.2% | 0.01% | +75.0% |
| Q4 2014 | $32,062,000 | +9.9% | 3,322,440 | +3.6% | 0.00% | 0.0% |
| Q3 2014 | $29,187,000 | -7.9% | 3,207,340 | 0.0% | 0.00% | 0.0% |
| Q2 2014 | $31,689,000 | -52.7% | 3,207,340 | -39.2% | 0.00% | -55.6% |
| Q1 2014 | $66,997,000 | -3.9% | 5,275,340 | +13.4% | 0.01% | -10.0% |
| Q4 2013 | $69,713,000 | +37.6% | 4,650,640 | +1.3% | 0.01% | +25.0% |
| Q3 2013 | $50,665,000 | +39.0% | 4,589,140 | 0.0% | 0.01% | +33.3% |
| Q2 2013 | $36,438,000 | – | 4,589,140 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
| BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
| SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
| Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
| Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
| PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
| Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
| Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
| Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |